Synlab AG
XETRA:SYAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.8119
12.0279
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Synlab AG
Synlab AG
Cash from Financing Activities
Synlab AG
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Synlab AG
XETRA:SYAB
|
Cash from Financing Activities
-€825.2m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
Cash from Financing Activities
-€2.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-52%
|
|
|
Fresenius SE & Co KGaA
XETRA:FRE
|
Cash from Financing Activities
-€2.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Vita 34 AG
XETRA:V3V
|
Cash from Financing Activities
-€8.7m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-35%
|
|
|
E
|
Euroeyes International Eye Clinic Ltd
HKEX:1846
|
Cash from Financing Activities
-HK$102.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Fresenius Medical Care AG
XMUN:FME
|
Cash from Financing Activities
-€2.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-52%
|
|
Synlab AG
Glance View
Synlab AG is a clinical laboratory and medical diagnostic services company. The company is headquartered in Muenchen, Bayern and currently employs 27,337 full-time employees. The firm is engaged in laboratory services for human and veterinary medicine, as well as environmental analysis.
See Also
What is Synlab AG's Cash from Financing Activities?
Cash from Financing Activities
-825.2m
EUR
Based on the financial report for Dec 31, 2023, Synlab AG's Cash from Financing Activities amounts to -825.2m EUR.
What is Synlab AG's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-47%
Over the last year, the Cash from Financing Activities growth was -158%. The average annual Cash from Financing Activities growth rates for Synlab AG have been -47% over the past three years .
You don't have any saved screeners yet
